Precision BioSciences (STU:PBS0) Altman Z2-Score: -8.59 (As of Jul. 07, 2026)


STU:PBS0 Precision BioSciences Inc STU:PBS0
45 GF Score
Price €7.18
GF Value €1.59
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Precision BioSciences Altman Z2-Score?

Precision BioSciences STU:PBS0 +1.13% 45 Altman Z2-Score is -8.59 as of Jul. 07, 2026. GuruFocus rates STU:PBS0 with a GF Score™ of 45/100 and a GF Value™ of €1.59 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,390 Biotechnology companies, Precision BioSciences ranks worse than 64.75% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Precision BioSciences has a Altman Z2-Score of -8.59, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Precision BioSciences's Altman Z2-Score or its related term are showing as below:

STU:PBS0' s Altman Z2-Score Range Over the Past 10 Years
Min: -22.22   Med: -3.8   Max: 3.7
Current: -8.59

During the past 9 years, Precision BioSciences's highest Altman Z2-Score was 3.70. The lowest was -22.22. And the median was -3.80.


Precision BioSciences  (STU:PBS0) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Precision BioSciences Altman Z2-Score Related Terms


Precision BioSciences Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Precision BioSciences's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precision BioSciences Altman Z2-Score Chart

Precision BioSciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only -1.15 -4.29 -8.00 -6.50 -6.89

Precision BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.92 -16.61 -22.22 -6.89 -8.59

STU:PBS0 vs NBP, HUMA, ORMP: Altman Z2-Score Comparison

For the Biotechnology subindustry, Precision BioSciences's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precision BioSciences Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Altman Z2-Score falls into.


STU:PBS0
45GF Score
Precision BioSciences Inc STU:PBS0
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Precision BioSciences Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Precision BioSciences's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.7015+3.26*-3.7989+6.72*-0.2994+1.05*1.1507
=-8.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was €124.47 Mil.
Total Current Assets was €94.02 Mil.
Total Current Liabilities was €6.71 Mil.
Retained Earnings was €-472.83 Mil.
Pre-Tax Income was -15.951 + 16.438 + -18.55 + -20.392 = €-38.46 Mil.
Interest Expense was -0.269 + -0.297 + -0.308 + -0.31 = €-1.18 Mil.
Total Liabilities was €58.64 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(94.019 - 6.708)/124.466
=0.7015

X2=Retained Earnings/Total Assets
=-472.834/124.466
=-3.7989

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-38.455 - -1.184)/124.466
=-0.2994

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(67.473 - 0)/58.638
=1.1507

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Precision BioSciences has a Altman Z2-Score of -8.59 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -8.59 mean?
Precision BioSciences (STU:PBS0) has a Altman Z2-Score of -8.59 as of Jul. 07, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Precision BioSciences and its competitors. According to the industry distribution chart, Precision BioSciences ranks #900 out of 1390 companies in the Biotechnology industry, placing it in the top 64.7%.
Is Precision BioSciences' Altman Z2-Score too high?
Precision BioSciences' current Altman Z2-Score is -8.59. Based on the distribution chart, Precision BioSciences ranks #900 out of 1390 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Precision BioSciences has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' Altman Z2-Score compare to NBP and HUMA?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #900 out of 1390 companies for Altman Z2-Score. This places Precision BioSciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Precision BioSciences and its competitors. Precision BioSciences's current Altman Z2-Score is -8.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (STU:PBS0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.59, compared to a current price of €7.18 — trading 351.6% above its estimated fair value. The current Altman Z2-Score is -8.59. Precision BioSciences' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Precision BioSciences (STU:PBS0), the current Altman Z2-Score is -8.59 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precision BioSciences (STU:PBS0) Overvalued in 2026?

Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued. The current stock price of €7.18 is trading 351.6% above its estimated GF Value™ of €1.59. GuruFocus considers Precision BioSciences to be Significantly Overvalued.

Key valuation signals for STU:PBS0:

  • Altman Z2-Score: -8.59
  • GF Value™: €1.59 vs. price of €7.18 (351.6% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STU:PBS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Precision BioSciences Business Description

Other Exchanges DTIL:USA
Address 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
45GF Score

Get the complete analysis for STU:PBS0

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.18
Price
€1.59
GF Value